% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

btimnextmicrosoft 80 posts  |  Last Activity: May 20, 2015 3:44 PM Member since: Oct 15, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • btimnextmicrosoft by btimnextmicrosoft May 20, 2015 3:44 PM Flag

    MRNA one of the few RNAI companies yet to propel above $2 range. I bought in after several recent key milestones. SMARTICLES continued clinical success. There delivery of next-gen drugs(RNAI/stem cells) is very lucrative and MRNA seems to have a unique and important platform with SMARTICLES.
    I also think the recent securing of key RNAi ip is key to MRNA's success and would think this would soon lead to major partnerships, mergers or a possible buyout. Lastly I thought Marina's new anti-tumor/white blood cell news sounded interesting.
    My 2 cents

  • btimnextmicrosoft by btimnextmicrosoft May 20, 2015 12:10 AM Flag

    Monday and Tuesdays 90% of the time
    Stock up:
    Thursdays and Fridays 90% of the time

  • Reply to

    BTX analysis -time to buy

    by headsupeyesclosed May 19, 2015 3:39 PM
    btimnextmicrosoft btimnextmicrosoft May 19, 2015 9:19 PM Flag

    August and Sept pop with investors buying in a month or two before these blockbuster products in 4th Quarter. Until then guessing it will coast. 4.50 seems like the bottom considering their subsidiary AST is $12.

  • btimnextmicrosoft by btimnextmicrosoft May 19, 2015 11:37 AM Flag

    Big pop due at that time

  • ALAMEDA, Calif.--(BUSINESS WIRE)--May 19, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the presentation of positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed to aid physicians in the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute, an international leader in basic biomedical research. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. Andrew Kossenkov, PhD, a senior member of Dr. Showe's laboratory and Managing Director of Wistar's Bioinformatics Facility, will present interim results from the study at the American Thoracic Society (ATS) International Conference during an oral presentation beginning at 2:45 PM MDT on Tuesday, May 19, 2015.

  • btimnextmicrosoft btimnextmicrosoft May 17, 2015 9:10 PM Flag

    Long term but huge rev product. Important thing to remember is that BTX retinal cells are zeno(animal) free, ACTC(Ocata)'s product is not.

  • btimnextmicrosoft btimnextmicrosoft May 17, 2015 9:07 PM Flag

    Time to buy!

  • Reply to

    Gate keeper to future therapies

    by ipstissueface May 16, 2015 4:27 PM
    btimnextmicrosoft btimnextmicrosoft May 17, 2015 9:05 PM Flag

    Best of breed.

  • Reply to

    BTX board or bashers? reiterate $50+ target

    by my_honest_opinion May 14, 2015 10:29 AM
    btimnextmicrosoft btimnextmicrosoft May 14, 2015 3:05 PM Flag

    Kingsley a smart man, that's why he hired Dr. West 7 years ago!

  • Biotimes ip domination of hESC will be huge now that the tide for both research AND therapeutics is turning from IPS cells to human embryonic stem cells. All three recent partners committing to our patented hESC platform.
    Next-gen biotech big pharma comin up!

  • Everyone but Michael West. Biotime has spent the last eight years acquiring the worlds majority of GMP hESC lines. Dr. West was one of the few that had the guts and smarts, all the rest played it safe running from the right wing religious yahoos. Now Biotime reaping the rewards with a monopoly of hESC ip and partnerships coming now just about every month.

    Sentiment: Strong Buy

  • Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world's understanding of how biology affects diseases such as diabetes, HIV/AIDS, and cancer.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 9:04 PM Flag

    Heads, let's get to $10 before contemplating $100!....all in good time.

    Btw our new partner is no small potatoes:
    Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world's understanding of how biology affects diseases such as diabetes, HIV/AIDS, and cancer.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 9:01 PM Flag

    ...with that said, all the more reason to invest in BTX while they are in the 'embryonic' stage.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 8:58 PM Flag

    Phil, BTX has six other subsidiaries besides AST, not all will IPO. A few likely will including OncoCyte, OrthoCyte and ReCyte.
    OrthoCyte long term will have 12 different kinds of 'off the shelf' cartilage progenitors for transplant. Clinical trial phase one results for knee cartilage regen will be out within three months. These hESC progenitors are combined with their extra-cellular matrix product called HyStem. Expect an OrthoCyte IPO in 2016 after it is clear these cartilage/ECM products work. Chances are they do since animal preclinical studies were very promising.
    OncoCyte will have bladder and breast cancer diagnostic products starting to hit the market end of 2015, with breast PanC-DX soon to follow. They also have nano-peptide anti-tumor ip that will start clinical trials likely by years end. Expect a OncoCyte IPO in late 2015 before revenues from PanC-DX start pouring in.
    ReCtye will have cardio, vascular and blood regen therapies entering clinical studies in 2016, so expect a late 2016/17 IPO unless they decide to take the world on by storm with a ACTC merger which is looking less likely last couple years.

  • Picks & shovels for tomorrow's gold mine:
    ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 22, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime's subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI's clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH's clinical collaborators, including medical research organizations intent on using the hES cells to develop and commercialize therapeutic products to treat human disease. The Agreement is a critical part of BioTime's strategy to leverage third party funding and generate future revenues by placing its hES cells in programs developing a wide array of therapeutic applications made possible with pluripotent stem cell technology, products that are currently not being developed by BioTime or its subsidiaries. Successful medical research organizations will need to obtain separate licenses from BioTime in order to advance their products based on ESI's hES cells into clinical trials and commercialization. Those licenses may entitle BioTime to receive additional revenues such as milestone payments related to the attainment of clinical trial and commercial milestones and royalties on product sales. BioTime and BioTime subsidiaries will retain the rights to manufacture their own stem cell-based products as well as to license rights to other third parties.

  • Reply to

    going up After Hours! 5,55 +1,82%

    by rios.facundo Apr 21, 2015 6:42 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 8:21 PM Flag

    Get in while we are still under $20....Gold mine!

  • Reply to


    by twicesilent23 Apr 21, 2015 4:33 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 5:10 PM Flag

    A couple days ago:
    A poster, including an abstract of the results of work by BioTime scientists with human embryonic stem cell-derived clonal brown adipocyte progenitors, presented by BioTime at the Keystone Symposia on Molecular and Cellular Biology.

  • Reply to

    OncoCyte IPO next

    by ipstissueface Apr 20, 2015 6:39 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 12:46 AM Flag

    Im ready to invest in the next subsidiary, bring it on! BTX is smart for introducing these subsidiaries early on before BTX grows, if BTX was a $100 there would be no need for this. Great way to expand the BTX brand!

  • btimnextmicrosoft by btimnextmicrosoft Apr 20, 2015 11:27 PM Flag

    Our ips cell competitor Cellular Dynamics(ips) has sold to fujifilm for 300mil. It's a lot, then again it's not. It's not a lot because ips cells will eventually be the future of regen medicine they say.....and it's a lot because ICEL I think basically abandoned ship. Why do I say this, a few reasons, 1) GE who signed a true testing deal a year or so ago with ICEL called it quits and recently sided with drug testing on 'the gold standard'(Biotimes hESC's).
    2)ICEL's stock price a month or so ago took a huge nose dive. 3) ICEL's CEO Jamie Thompson is one of the leadeing minds working with IPS cells and for him to sell the company for 300 MIL means ips cells are a long way off and maybe his bank of immune matching ips cells had less of a chance then previously thought for being the future cell solution.
    With that said 300mil all in all is a lot but when you look at their 800+ ips cell ip you would think it to be a bit short of expectation.

4.63+0.05(+1.09%)May 22 4:02 PMEDT